Spatial OMICS Market Size, Share, and Industry Analysis By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics, and Others), By Product Type (Instrument, Consumables, and Software), By Sample Type (FFPE and Fresh Frozen), By Workflow (Data Analysis, Sample Preparation, and Instrumental Analysis), By End-user (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, and Others), and Regional Forecast, 2025-2032

Spatial OMICS is a technology that allows for the measurement of gene activity in a tissue sample and spatially maps the location of activity. This approach provides a comprehensive understanding of cellular interactions and organizations within a tissue of interest, enabling the joint analysis of different molecular classes, such as transcriptomics, proteomics, and epigenomics. Spatial OMICS technologies have been developed to study the complexity of tissues, including cancer biology, and have the ability to reveal new insights into cellular states and functions.

Spatial OMICS technologies can identify specific regions in a tissue with differential transcript or protein abundance, define their interactions, and complement other methods in defining cellular phenotypes. These assays can be performed on the slide (in situ) using either microscopy or immunohistochemistry (IHC) and they vary in their spatial resolution, coverage, scale, and multiplexing capacity.

In recent years, the market growth for spatial OMICS products has been primarily influenced by advancements in spatial OMICS technology, including improved imaging techniques, data analysis algorithms, and bioinformatics tools. These significant advances have made spatial OMICS products more accessible and cost-effective, driving market growth. Furthermore, these technological advancements encourage key players to sign collaboration agreements and launch novel spatial OMICS products, contributing to market growth. For instance, in April 2022, Bruker announced the key innovations for spatial multiomics, single-cell proteomics, and cell-line, tissue, and plasma proteomics cancer research.

The growing burden of chronic diseases such as cancer and neurological disorders is fueling the demand for spatial OMICS products. For instance, in 2023, according to the Pan American Health Organization, the global cancer burden is projected to increase by nearly 60.0% or 30.0 million new cancer cases by 2040 in the next two decades, with a huge increase in low- and middle-income countries.

The spatial OMICS products are being increasingly used for disease diagnosis, prognosis, and treatment monitoring. The spatial OMICS technologies provide the capability to map the spatial pattern in tissue landscape, particularly focusing on discovering the spatial composition of tumors and spatial heterogeneity of tumors, which increases their demand.

Moreover, the rising demand for personalized medicine contributes to the growth of spatial OMICS products, allowing for deeper analysis of complex diseases at the single-cell level. In addition, it enables  researchers to understand disease mechanisms better and develop personalized treatment options, driving the adoption of spatial OMICS products. Furthermore, the expansion of pharmaceutical and biotechnology companies significantly boosts the spatial OMICS market growth, increasing the utilization of spatial OMICS products for biomarker identification, drug discovery, and clinical trials.

The COVID-19 pandemic witnessed a positive impact on the global spatial OMICS market. The broad research into understanding COVID-19 infections led to an increased focus on the use of spatial technologies and other OMICS studies, which propelled the demand for spatial OMICS products during the COVID-19 pandemic.

In addition, various companies in the market offered products for spatial OMICS studies. By utilizing these products, researchers were able to generate extensive datasets of tissue images and molecular data from COVID-19 decedents. This contributed to the surge of the market during 2020 of the pandemic.

• For instance, the GeoMx Digital Spatial Profiler (DSP) developed by NanoString enabled the spatial studies of the SARS-CoV-2 virus and host response during the pandemic. This product helped researchers to enhance their understanding of COVID-19 infection.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Countries/Sub-Regions, 2023


• Technological Advancement in Spatial OMICS Market


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the market  

Segmentation

Analysis by Product Type

Based on product type, the instrument segment is expected to hold a significant share of the global spatial OMICS market during the forecast period due to its crucial role in enabling spatial analysis. Instruments plays a vital role in facilitating spatial OMICS research by providing the necessary tools and technologies for spatial analysis. This segment is essential for conducting experiments, capturing spatial data, and generating insights, making it a key component driving the growth and advancement of spatial OMICS technologies. Additionally, the demand for advanced instruments with enhanced capabilities for spatial analysis is expected to encourage key players to launch novel products.

• For instance, in March 2022, Bruker’s division, Canopy Biosciences, launched the next-generation ChipCytometry instrument, CellScape system for spatial biology with sub-cellular resolution. These launches further drive the growth of this segment, contributing significantly to the global market growth.

Regional Analysis

North America is estimated to hold a noteworthy market share of the spatial OMICS market and expand more significantly during the forecast timeframe. The growth is primarily attributed to the high incidence of cancer in this region, which increases the demand for spatial OMICS in this region. Furthermore, the existence of key pharmaceutical and biotechnology companies and well-established healthcare infrastructure in the region is expected to surge the adoption of spatial OMICs, driving the market growth in North America.

• For instance, in January 2023, according to the American Cancer Society Journal, an estimated 1,958,310 new cancer cases were anticipated to occur in the U.S. This high incidence of cancer considerably spurred the demand for spatial OMICS products, driving the market share of North America.

The Asia Pacific market is projected to expand at a substantial CAGR during the forecast period. Rising investment in research and development initiatives by governments, academic institutions, and healthcare organizations in the field of spatial OMICS is expected to boost the market growth in this region. Moreover, this significant investment is projected to drive innovation and accelerate the commercialization of new spatial OMICS products, contributing to the regional market growth.

Key Players Covered

The report includes the profiles of key players such as 10x Genomics, S2 Genomics, Inc., NanoString Technologies, Inc., DH Life Sciences, LLC., Rebus Biosystems, Inc., Akoya Biosciences, Inc., Ionpath, Inc., Ultivue, Inc., BioSpyder, Inc., Bruker, and Diagenode Diagnostics (Hologic, Inc).

Key Industry Developments

• In February 2024, DNAnexus, Inc., collaborated with Curio Bioscience to streamline and simplify data analysis for high-resolution, whole transcriptome spatial mapping studies, allowing Curio Bioscience to utilize the DNAnexus Precision Health Data Cloud and its intuitive analysis environment.


• In June 2023, OMAPiX entered into a strategic partnership with spatial biology platform providers Vizgen, Inc., Ultivue, Inc., and Resolve Biosciences to accelerate life science research and drug development.

In November 2022, Akoya Biosciences, Inc. announced the launch of PhenoCode Signature Panels to enhance the development of predictive biomarkers for cancer immunotherapy.